Literature DB >> 23933953

Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial.

Daniël H van Raalte1, Michaela Diamant, D Margriet Ouwens, Richard G Ijzerman, Margot M L Linssen, Bruno Guigas, Etto C Eringa, Erik H Serné.   

Abstract

AIMS/HYPOTHESIS: Glucocorticoids (GCs) are widely used anti-inflammatory agents that frequently induce side effects, including insulin resistance, diabetes and hypertension. Here, we investigated the contribution of microvascular dysfunction to the development of these adverse effects in healthy men.
METHODS: In a randomised, placebo-controlled, dose-response intervention study, 32 healthy normoglycaemic men (age: 21 ± 2 years; BMI: 21.9 ± 1.7 kg/m(2)) were allocated to receive prednisolone 30 mg once daily (n = 12), prednisolone 7.5 mg once daily (n = 12) or placebo (n = 8) for 2 weeks using block randomisation. A central office performed the treatment allocation, and medication was dispersed by the hospital pharmacy that was also blinded. Treatment allocation was kept in concealed envelopes. Participants, study personnel conducting the measures and assessing the outcome were blinded to group assignment. The study was conducted at a university hospital. Primary endpoint was prednisolone-induced changes in microvascular function, which was assessed by capillary microscopy. Insulin sensitivity was determined by hyperinsulinaemic-euglycaemic clamp and postprandial glycaemic excursions by standardised meal tests.
RESULTS: Compared with placebo, prednisolone 7.5 mg and 30 mg decreased insulin-stimulated capillary recruitment by 9 ± 4% and 17 ± 3%, respectively (p < 0.01). In addition, prednisolone 7.5 mg and 30 mg reduced insulin sensitivity (M value) by -11.4 ± 4.5 μmol kg(-1) min(-1) and -25.1 ± 4.1 μmol kg(-1) min(-1) (p < 0.001) and increased postprandial glucose levels by 11 ± 5% and 27 ± 9% (p < 0.001), respectively. Only high-dose prednisolone increased systolic blood pressure (6 ± 1.2 mmHg, p = 0.006). Prednisolone-induced changes in insulin-stimulated capillary recruitment were associated with insulin sensitivity (r = +0.76; p < 0.001), postprandial glucose concentrations (r = -0.52; p < 0.03) and systolic blood pressure (r = -0.62; p < 0.001). Prednisolone increased resistin concentrations, which were negatively related to insulin-stimulated capillary recruitment (r = -0.40; p = 0.03). No effects were noted on adiponectin and leptin concentrations. Prednisolone treatment was well tolerated; none of the participants left the study. CONCLUSIONS/
INTERPRETATION: Prednisolone-induced impairment of insulin-stimulated capillary recruitment was paralleled by insulin resistance, increased postprandial glucose levels, hypertension and increased circulating resistin concentrations in healthy men. We propose that GC-induced impairments of microvascular function may contribute to the adverse effects of GC treatment on glucose metabolism and blood pressure. TRIAL REGISTRATION: isrctn.org ISRTCN 78149983. FUNDING: The study was funded by the Dutch Top Institute Pharma T1-106.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23933953     DOI: 10.1007/s00125-013-3016-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  35 in total

1.  Risk of diabetes associated with prescribed glucocorticoids in a large population.

Authors:  Martin C Gulliford; Judith Charlton; Radoslav Latinovic
Journal:  Diabetes Care       Date:  2006-12       Impact factor: 19.112

Review 2.  Glucocorticoids and cardiovascular disease.

Authors:  Brian R Walker
Journal:  Eur J Endocrinol       Date:  2007-11       Impact factor: 6.664

3.  Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature.

Authors:  Zhenqi Liu; Jia Liu; Linda A Jahn; Dale E Fowler; Eugene J Barrett
Journal:  J Clin Endocrinol Metab       Date:  2009-06-30       Impact factor: 5.958

4.  Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle.

Authors:  Lucy H Clerk; Michelle A Vincent; Linda A Jahn; Zhenqi Liu; Jonathan R Lindner; Eugene J Barrett
Journal:  Diabetes       Date:  2006-05       Impact factor: 9.461

Review 5.  Glucocorticoid-induced hypertension: from mouse to man.

Authors:  J A Whitworth; C G Schyvens; Y Zhang; G J Mangos; J J Kelly
Journal:  Clin Exp Pharmacol Physiol       Date:  2001-12       Impact factor: 2.557

6.  Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men.

Authors:  Daniël H van Raalte; Valentina Nofrate; Mathijs C Bunck; Thijs van Iersel; Jeroen Elassaiss Schaap; Ulla K Nässander; Robert J Heine; Andrea Mari; Wim H A Dokter; Michaela Diamant
Journal:  Eur J Endocrinol       Date:  2010-02-02       Impact factor: 6.664

Review 7.  Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?

Authors:  D H van Raalte; D M Ouwens; M Diamant
Journal:  Eur J Clin Invest       Date:  2009-02       Impact factor: 4.686

Review 8.  Cardiovascular actions of insulin.

Authors:  Ranganath Muniyappa; Monica Montagnani; Kwang Kon Koh; Michael J Quon
Journal:  Endocr Rev       Date:  2007-05-24       Impact factor: 19.871

Review 9.  Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease.

Authors:  Rick I Meijer; Erik H Serne; Yvo M Smulders; Victor W M van Hinsbergh; John S Yudkin; Etto C Eringa
Journal:  Curr Diab Rep       Date:  2011-06       Impact factor: 4.810

10.  Perivascular adipose tissue control of insulin-induced vasoreactivity in muscle is impaired in db/db mice.

Authors:  Rick I Meijer; Wineke Bakker; Caro-Lynn A F Alta; Pieter Sipkema; John S Yudkin; Benoit Viollet; Erik A Richter; Yvo M Smulders; Victor W M van Hinsbergh; Erik H Serné; Etto C Eringa
Journal:  Diabetes       Date:  2012-10-09       Impact factor: 9.461

View more
  6 in total

1.  Michaela Diamant, 11 April 1962-9 April 2014.

Authors:  Robert J Heine; Hannele Yki-Järvinen; Steven E Kahn; Daniel H van Raalte
Journal:  Diabetologia       Date:  2014-05-06       Impact factor: 10.122

2.  Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids.

Authors:  Nantia Othonos; Thomas Marjot; Conor Woods; Jonathan M Hazlehurst; Nikolaos Nikolaou; Riccardo Pofi; Sarah White; Ilaria Bonaventura; Craig Webster; Joanne Duffy; Thomas Cornfield; Ahmad Moolla; Andrea M Isidori; Leanne Hodson; Jeremy W Tomlinson
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

3.  Single-dose prednisolone alters endocrine and haematologic responses and exercise performance in men.

Authors:  Alexander Tacey; Lewan Parker; Bu B Yeap; John Joseph; Ee M Lim; Andrew Garnham; David L Hare; Tara Brennan-Speranza; Itamar Levinger
Journal:  Endocr Connect       Date:  2019-02       Impact factor: 3.335

Review 4.  Relationship Between Glucocorticoids and Insulin Resistance in Healthy Individuals.

Authors:  Peng-Zhen Zhou; Yong-Mei Zhu; Guang-Hui Zou; Yu-Xia Sun; Xiao-Lin Xiu; Xin Huang; Qun-Hui Zhang
Journal:  Med Sci Monit       Date:  2016-06-03

5.  Effects of Incretin-Based Therapies on Neuro-Cardiovascular Dynamic Changes Induced by High Fat Diet in Rats.

Authors:  Silvio Rodrigues Marques-Neto; Raquel Carvalho Castiglione; Aiza Pontes; Dahienne Ferreira Oliveira; Emanuelle Baptista Ferraz; José Hamilton Matheus Nascimento; Eliete Bouskela
Journal:  PLoS One       Date:  2016-02-01       Impact factor: 3.240

6.  The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring.

Authors:  Yusuke Yata; Michihiro Hosojima; Hideyuki Kabasawa; Tomomi Ishikawa; Ryohei Kaseda; Noriaki Iino; Yoshiki Suzuki; Akihiko Saito; Ichiei Narita
Journal:  Intern Med       Date:  2017-09-06       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.